Browse News
Filter News
Found 804,928 articles
-
Following in the footsteps of Bristol Myers Squibb and Eli Lilly, AstraZeneca on Tuesday jumped into the radiopharmaceuticals space by acquiring Fusion Pharmaceuticals in a deal worth $2.4 billion.
-
Orchard Therapeutics on Monday secured the FDA’s first approval for an autologous gene therapy to treat the rare metabolic disease metachromatic leukodystrophy in children.
-
CB Scientific, Inc. Concludes its Annual Meeting of Stockholders
3/19/2024
CB Scientific, Inc., a designer, manufacturer and distributor of non-invasive ambulatory cardiac monitoring products and services, announced that the company successfully concluded its Annual Meeting of Stockholders on Thursday, March 14, 2024 as planned.
-
Health Canada Accepts for Review New Drug Submission for Tofersen for Treatment of Rare, Genetic Form of ALS
3/19/2024
Biogen Canada Inc. announced that Health Canada has accepted for review a New Drug Submission for tofersen for the treatment of amyotrophic lateral sclerosis in adults who have a mutation in the superoxide dismutase 1 gene.
-
Cytovale's Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application
3/19/2024
Cytovale® announced new data that demonstrates how its IntelliSep® test reduced cost of care and improved efficiency of sepsis care for a large U.S. academic center.
-
Ferinject® approved by Health Canada for the treatment of iron deficiency anemia in adult and pediatric patients and iron deficiency in adult patients with heart failure
3/19/2024
CSL Vifor announced that Health Canada has authorized Ferinject for the intravenous treatment of iron deficiency anemia in adult and pediatric patients one year of age and older when oral iron preparations are not tolerated or are ineffective, as well as for the treatment of iron deficiency in adult patients with heart failure and New York Heart Association class II/III* to improve exercise capacity.
-
Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer
3/19/2024
Conduit Pharmaceuticals Inc. announced the appointment of Dr. Joanne Holland as Chief Scientific Officer.
-
Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
3/19/2024
Revive Therapeutics Ltd. announced that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID.
-
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
3/19/2024
Tourmaline Bio, Inc. announced its financial results for the fourth quarter and year ended December 31, 2023 and outlined recent business highlights.
-
LSL Pharma Group Secures $6.44 Million as the First Closing of Concurrent Non-Brokered Private Placements
3/19/2024
LSL PHARMA GROUP INC., a Canadian integrated pharmaceutical company, announced the closing on March 18, 2024 of non-brokered private placements for $6.44 million representing the first closing of the $8.0 million combined financings announced on March 7, 2024.
-
Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depressive Disorder
3/19/2024
Axsome Therapeutics, Inc. announced the first patient has been dosed in the PARADIGM Phase 3 trial of solriamfetol, an investigational treatment for major depressive disorder.
-
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
3/19/2024
Century Therapeutics announced that members of the management team will participate in a fireside chat a the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference on Tuesday, March 26th, 2024 at 1:30pm ET.
-
Kraig Biocraft Laboratories Brings Leading Sericulture Expert from India for Launch of Spring Production Trials
3/19/2024
Kraig Biocraft Laboratories, Inc., announces that Dr. Nirmal Kumar, a globally recognized expert in sericulture, will join the Company’s Senior Management in Vietnam to supervise the start of the spring production trials and the launch of the BAM-1 hybrid.
-
SPEVIGO® approved for expanded indications in China and the US
3/19/2024
Boehringer Ingelheim announced that the US FDA has approved SPEVIGO® injection for the treatment of generalized pustular psoriasis in adults and pediatric patients aged 12 and above weighing ≥40 kg.5 This approval follows the Chinese National Medical Products Administration’s recent approval of SPEVIGO® for the reduction of occurrence of generalized pustular psoriasis in adolescents from 12 years of age with a body weight ≥40 kg and adults.
-
Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study
3/19/2024
Asieris Pharmaceuticals announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18.
-
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis
3/19/2024
Vicore Pharma Holding AB announced FDA Breakthrough Device Designation status for AlmeeTM, a 9-week digital cognitive behavioral therapy, to be used as an adjunct treatment of anxiety symptoms related to PF.
-
CGI selected by Centers for Medicare & Medicaid Services to improve Medicare access for more than 65 million beneficiaries nationwide
3/19/2024
CGI Federal Inc., a wholly-owned U.S. operating subsidiary of CGI Inc., has been awarded a single award, firm-fixed price contract by the Centers for Medicare & Medicaid Services to help improve access to Medicare for millions of beneficiaries by modernizing the agency's Health Plan Management System.
-
Sanyou Bio and BioGeometry join forces to create a next-generation Antibody Drug Discovery Platform driven by AIGC
3/19/2024
Recently, BioGeometry and Sanyou Bio jointly announced the signing of a strategic partnership agreement.
-
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
3/19/2024
Pluri Inc., a leading biotechnology company that transforms cells into solutions that promote global wellbeing and sustainability, announced its participation in the following upcoming conferences.
-
Solventum Hosts Inaugural Investor Day Ahead of Its Planned Spinoff from 3M
3/19/2024
Solventum will host its inaugural Investor Day in New York City ahead of its planned spinoff from 3M.